- Home
- RRR vs DYN Comparison
RRR vs DYN Comparison
Compare RRR & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRR | DYN |
|---|---|---|
| Founded | 1976 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.0B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RRR | DYN |
|---|---|---|
| Price | $52.95 | $17.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | ★ $69.69 | $37.00 |
| AVG Volume (30 Days) | 875.1K | ★ 1.7M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | ★ 23.32 | N/A |
| EPS | ★ 3.12 | N/A |
| Revenue | ★ $2,011,483,000.00 | N/A |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $4.62 | N/A |
| P/E Ratio | $17.47 | ★ N/A |
| Revenue Growth | ★ 3.74 | N/A |
| 52 Week Low | $43.16 | $8.25 |
| 52 Week High | $68.99 | $25.00 |
Technical Indicators
Market Signals| Indicator | RRR | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 36.33 | 41.97 |
| Support Level | $52.41 | $16.47 |
| Resistance Level | $59.48 | $19.65 |
| Average True Range (ATR) | 1.71 | 0.98 |
| MACD | -0.12 | -0.30 |
| Stochastic Oscillator | 22.01 | 5.45 |
Price Performance
Historical ComparisonAbout RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos, followed by Food and Beverages, Rooms and others.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.